SGLT2 inhibitors tied to double the risk of genital infections
A large population-based cohort study quantifies the risk compared with other diabetes drug classes
SGLT2 inhibitor initiation by patients with type 2 diabetes is associated with a 2-4 times increased risk of genital tract infections compared with other classes of antihyperglycaemics, real-world data confirm.
Researchers have drawn on UK primary care and Canadian administrative healthcare data for more than 50,000 new metformin users initiating second-line agents to compare their risk of the gamut of genital infections, ranging from thrush to Fournier’s gangrene.
